Nitroglycerin: a comprehensive review in cancer therapy DOI Creative Commons

Mélina Meunier,

Aline Yammine,

Ali Bettaı̈eb

et al.

Cell Death and Disease, Journal Year: 2023, Volume and Issue: 14(5)

Published: May 12, 2023

Abstract Nitroglycerin (NTG) is a prodrug that has long been used in clinical practice for the treatment of angina pectoris. The biotransformation NTG and subsequent release nitric oxide (NO) responsible its vasodilatating property. Because remarkable ambivalence NO cancer disease, either protumorigenic or antitumorigenic (partly dependent on low high concentrations), harnessing therapeutic potential gain interest to improve standard therapies oncology. Cancer resistance remains greatest challenge overcome order management patients. As releasing agent, subject several preclinical studies combinatorial anticancer therapy. Here, we provide an overview use therapy foresee new avenues.

Language: Английский

The role of aldehyde dehydrogenase 2 in cardiovascular disease DOI
Jian Zhang, Yunyun Guo, Xiangkai Zhao

et al.

Nature Reviews Cardiology, Journal Year: 2023, Volume and Issue: 20(7), P. 495 - 509

Published: Feb. 13, 2023

Language: Английский

Citations

73
Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets DOI Creative Commons
Jie Xia, Siqin Li, Suling Liu

et al.

MedComm, Journal Year: 2023, Volume and Issue: 4(1)

Published: Jan. 16, 2023

The family of aldehyde dehydrogenases (ALDHs) contains 19 isozymes and is involved in the oxidation endogenous exogenous aldehydes to carboxylic acids, which contributes cellular tissue homeostasis. ALDHs play essential parts detoxification, biosynthesis, antioxidants, are important value for cell proliferation, differentiation, survival normal body tissues. However, frequently dysregulated associated with various diseases like Alzheimer's disease, Parkinson's especially solid tumors. Notably, involvement tumor progression responsible maintenance stem-cell-like phenotype, triggering rapid aggressive clinical progressions. have captured increasing attention as biomarkers disease diagnosis prognosis. Nevertheless, these require further longitudinal studies large populations broad application. This review summarizes our current knowledge regarding potential tumors several non-tumor diseases, well recent advances understanding functions underlying molecular mechanisms development. Finally, we discuss therapeutic therapy an emphasis on their implications.

Language: Английский

Citations

43
The strategies to cure cancer patients by eradicating cancer stem-like cells DOI Creative Commons

Yansui Mai,

Jiyan Su,

Chuan Yang

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Oct. 18, 2023

Abstract Cancer stem-like cells (CSCs), a subpopulation of cancer cells, possess remarkable capability in proliferation, self-renewal, and differentiation. Their presence is recognized as crucial factor contributing to tumor progression metastasis. CSCs have garnered significant attention therapeutic focus an etiologic root treatment-resistant cells. Increasing evidence indicated that specific biomarkers, aberrant activated pathways, immunosuppressive microenvironment (TME), immunoevasion are considered the culprits occurrence maintenance properties including multi-directional Targeting CSC stemness-associated TME, inducing differentiation improve eradication and, therefore, treatment. This review comprehensively summarized these targeted therapies, along with their current status clinical trials. By exploring implementing strategies aimed at eradicating CSCs, researchers aim treatment outcomes overcome challenges posed by CSC-mediated therapy resistance.

Language: Английский

Citations

43
Neural-cancer Crosstalk: Reciprocal Molecular Circuits Driving Gastric Tumorigenesis and Emerging Therapeutic Opportunities DOI
Ning Li, Huili Tong,

Wenqing Hou

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217589 - 217589

Published: Feb. 1, 2025

Language: Английский

Citations

2
A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer DOI Creative Commons
Haoyu Wang, Jingchun Liu, Yang Jiang

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Aug. 8, 2022

Tumor mutational burden (TMB) has been reported to determine the response immunotherapy, thus affecting patient's prognosis in many cancers. However, it is unclear whether TMB or TMB-related signature could be used as prognostic indicators for ovarian cancer (OC), its potential association with immune infiltration remains poorly understood. Therefore, this study aimed develop a novel risk model (TMBrisk) predict of OC patients on basis exploring genes, and explore between TMB/TMBrisk infiltration. The landscape, scores, correlations clinical characteristics were investigated Cancer Genome Atlas (TCGA)-OV cohort. Differentially expressed gene (DEG) analyses weighted co-expression network analysis (WGCNA) performed derive genes. TMBrisk was constructed by Cox regression further validated Gene Expression Omnibus (GEO) datasets. mRNA protein expression levels biological functions hub genes verified through Profiling Interactive Analysis (GEPIA), GSCA Lite, Human Protein (HPA) database, RT-qPCR. TMBrisk-related phenotypes analyzed function enrichment tumor signature. Potential therapeutic regimens inferred utilizing Genomics Drug Sensitivity (GDSC) database connectivity map (CMap). According our results, higher associated better survival CD8+ T cell, regulatory NK cell developed based CBWD1, ST7L, RFX5-AS1, C3orf38, LRFN1, LEMD1, HMGB1. High identified poor factor TCGA GEO datasets; high-TMBrisk group comprised more higher-grade (G2 G3) advanced stage (stage III/IV) tumors. Meanwhile, an immunosuppressive phenotype, less majority immunocytes several human leukocyte antigen (HLA) family. Moreover, nomogram containing showed strong predictive ability demonstrated time-dependent ROC analysis. Overall, prognosis, evaluate infiltration, discover new OC, which very promising promotion.

Language: Английский

Citations

32
Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma DOI

Hongxing Zhao,

Yuhang Ling,

Jie He

et al.

Drug Resistance Updates, Journal Year: 2024, Volume and Issue: 74, P. 101084 - 101084

Published: April 17, 2024

Language: Английский

Citations

9
Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research DOI Creative Commons
Boram Son, Wonhwa Lee, Hyeon-Jeong Kim

et al.

Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(9)

Published: Sept. 30, 2024

Language: Английский

Citations

9
Increased heterogeneity in expression of genes associated with cancer progression and drug resistance DOI Creative Commons

Anwesha Bose,

Subhasis Datta, R. Mandal

et al.

Translational Oncology, Journal Year: 2024, Volume and Issue: 41, P. 101879 - 101879

Published: Jan. 22, 2024

Fluctuations in the number of regulatory molecules and differences timings molecular events can generate variation gene expression among genetically identical cells same environmental condition. This variation, termed as noise, create metabolic state cellular functions, leading to phenotypic heterogeneity. Expression noise heterogeneity have been recognized important contributors intra-tumor heterogeneity, associated with cancer growth, progression, therapy resistance. However, how changes progression actual patients has remained poorly explored. Such an analysis, through identification genes increasing provide valuable insights into generation could implications for understanding immune-suppression, drug tolerance In this work, we performed a genome-wide using single-cell RNA-seq data lung adenocarcinoma at different stages cancer. We identified 37 epithelial that showed trend many which were also EMT found several these was positively mitochondrial genes, suggesting role mitochondria addition, uncovered substantial sample-specific profiles personalized prognosis treatment.

Language: Английский

Citations

7
Integration of microbiome, metabolomics and transcriptome for in-depth understanding of berberine attenuates AOM/DSS-induced colitis-associated colorectal cancer DOI Open Access
Mengxia Wang, Yan Ma,

Guodong Yu

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 179, P. 117292 - 117292

Published: Aug. 15, 2024

A type of colorectal cancer (CRC)，Colitis-associated (CAC)， is closely associated with chronic inflammation and gut microbiota dysbiosis. Berberine (BBR) has a long history in the treatment intestinal diseases, which been reported to inhibit colitis CRC. However, mechanism its action still unclear. Here, this study aimed explore potential protective effects BBR on azoxymethane (AOM)/dextransulfate sodium (DSS)-induced tumor mice, elucidate molecular mechanisms by microbiota, genes metabolic alterations. The results showed that inhibited improved function mucosal barrier ameliorate AOM/DSS-induced colitis. And significantly reduced development ki-67 expression tissue along promoted apoptosis. Through analysis based 16 S rRNA gene, we found imbalance were characterized an increase beneficial bacteria, for instance Akkermanisa, Lactobacillus, Bacteroides uniformis acidifaciens. In addition, transcriptome regulated colonic epithelial signaling pathway CAC mice particularly tryptophan metabolism Wnt pathway. Notably, resulted enrichment amino acids microbiota-derived SCFA metabolites. summary, our research findings suggest microbiota-amino acid metabolism-Wnt axis plays critical role maintaining homeostasis, may provide new insights into inhibitory colon cancer.

Language: Английский

Citations

7
Metabolic and alcohol-associated liver disease (MetALD): a representation of duality DOI Creative Commons
Hector Leal-Lassalle,

Olga Estévez-Vázquez,

Francisco Javier Cubero

et al.

npj gut and liver., Journal Year: 2025, Volume and Issue: 2(1)

Published: Jan. 10, 2025

MetALD is a recently coined term that refers to systemic entity describe patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and simultaneous moderate alcohol consumption. The deleterious association of risk factors synergistically increases the development steatohepatitis, fibrosis, hepatocellular carcinoma (HCC). Despite its increasing incidence, pathophysiological mechanisms triggering damage in remain unclear. This review aims summarize prevalence, pathophysiology MetALD, taking into account latest clinical translational aspects.

Language: Английский

Citations

1